mRESVIA is Moderna's second mRNA-based vaccine and will be shipped in prefilled syringes, a desirable feature that could save clinical time, prevent errors.
All News
Advertisement
Advertisement
The interactive tool provides clinicians and patients a real-time look at GLP-1RA availability.
The dual interleukin-4, 13 inhibitor reduced COPD exacerbation rates by as much as 34% for individuals with COPD with type 2 inflammation, Bhatt explains.
FDA has no concerns about the "approvability" of dupilumab for the new indication but needs additional time to review phase 3 data it requested early in May.
Your daily dose of the clinical news you may have missed.
Primary care clinicians are essential to maximizing evidence-based midlife care for women, according to Professor of Obstetrics & Gynecology JoAnn Pinkerton, MD.
Findings from 2 early stage studies reported at a recent clinical meeting support the safety and tolerability of the GLP-1RA in persons with substance use disorders.
The risk of mortality was not higher for women with vs without PMD overall but was particularly elevated for young women and for suicide across age of PMD diagnosis.
The novel dual neurokinin-1,3 antagonist reduced VMS after just 1 week of treatment, Pinkerton said, and improved sleep and quality of life, as well. Hear more.
These 7 questions are based on the most recent update to the guidelines by the Women's Preventive Services Initiative, including supporting resources.
Advertisement
Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.
Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.
Your daily dose of the clinical news you may have missed.
Pulmonology experts agreed that adopting race-neutral diagnostic and research practices could help mitigate a range of inequities faced by minority populations.
The pluripotent GLP-1 mimetic reduced risk for renal disease endpoints by 24% and MACE by 18% plus significantly retarded decline in eGFR vs placebo, study authors reported.
Findings underscore a need for public health initiatives to educate vulnerable populations on cardiometabolic risks, researchers report.
Your daily dose of the clinical news you may have missed.
A concise update on legal status, FDA approvals, patient safety, and public perception.
Your daily dose of the clinical news you may have missed.
The 3% decline in 2023 compared with 2022 is "heartening news," CDC's Houry says, but the mission is far from accomplished.
Advertisement
Advertisement
Advertisement
